Animal model for perimenopause and menopause and methods of inducing ovarian failure

a technology of perimenopause and menopause, which is applied in the field of animal models for perimenopause and menopause and methods of inducing ovarian failure, can solve the problems of increasing life expectancy, affecting the incidence of many age-related diseases, and many health risks associated with menopaus

Inactive Publication Date: 2010-03-04
THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This model provides a more accurate representation of human menopause, enabling the investigation of physiological and molecular endpoints related to menopause-associated health risks, offering a superior alternative to existing models by maintaining the ovaries and inducing characteristics of perimenopause and menopause without adverse effects on other body organs.

Problems solved by technology

Obviously, in the future, the increase in life expectancy will impact the incidence of many age-related diseases and require aggressive intervention during the postmenopausal years.
Many health risks are known to be associated with menopause.
However, the HERS study recently reported that HRT in post menopausal women did not prevent recurrent myocardial infarction (4).
Furthermore, there is a significant debate over the advantages and disadvantages of using HRT in postmenopausal women relative to a potential increase in both breast and ovarian cancer risks (5, 6, 7).
However, the vast majority do not develop to ovulation, but undergo cell death by atresia.
As a result, the pool of primordial follicles gradually becomes depleted and ultimately, ovarian failure (menopause) ensues (8).
As the pool of primordial follicles is depleted, this compromises the numbers of developing pre-ovulatory follicles.
In researching menopause, a limited amount of mechanistic information can be obtained from studies in middle-aged women.
Although nonhuman primates most closely resemble humans, there are disadvantages in using them in the study of menopause.
These include limitations on the number of animals, costly acquisition and housing expenses, and lengthy life spans, with reproductive senescence occurring late in life (9).
While this approach mimics the loss of 17β-estradiol seen in menopause, it lacks consideration of the physiological contributions of the postmenopausal ovary.
However, because there has not heretofore been an adequate animal model of the postmenopausal ovary, this issue has not been directly investigated.
However, the time it takes from dosing of the animals until premature ovarian failure occurs is too long in order to use animals prepared in such a manner as a model for menopause.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Animal model for perimenopause and menopause and methods of inducing ovarian failure
  • Animal model for perimenopause and menopause and methods of inducing ovarian failure
  • Animal model for perimenopause and menopause and methods of inducing ovarian failure

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0063]Treatment with VCD reduced (p1 mice (FIG. 1). Primordial follicles were reduced at 80 mg / kg to 12.1% of control, 160 mg / kg (80 mg / kg, 2× daily, and 160 mg / kg 1× daily) 0% of control, 240 mg / kg (80 mg / kg 3× daily) 2.1% of control, 240 mg / kg (240 mg / kg 1× daily) 0% of control, and 320 mg / kg (160 mg / kg 2× daily) 0% of control. Primary follicles were reduced at 80 mg / kg to 38.6% of control, 160 mg / kg (160 1× daily) 2.8% of control, 160 mg / kg (80 mg / kg 2× daily) 11.3% of control, 240 mg / kg (80 mg / kg 3× daily) 5.1% of control, 240 mg / kg (240 mg / kg 1× daily) 0% of control and 320 mg / kg (160 mg / kg 2× daily) 0.6% of control.

[0064]Treatment with VCD (160 mg / kg, i.p.) for=15 days reduced (p<0.05) primary and primordial follicle numbers progressively over time (FIG. 2A). By d46 following commencement of 15d of treatment, all follicle pools were substantially depleted (p<0.05) relative to control. There were no primordial follicles and primary, secondary and antral follicles were 0.5%, 0.7...

example 2

Range Finding Experiment with Alzet Minipumps to Determine the No-Observable-Adverse-Effect-Level (NOAEL) of VCD and Verify Primordial and Primary Follicle Depletion

[0083]We will use B6C3F1 mice because they are the most completely characterized mouse strain using multiple injections of VCD. The 160 mg / kg / d dose injected i.p. for 15d yields the greatest acceleration of follicle depletion via a single injection without adverse effects. We know that if the total VCD dose delivered over 15d (2400 mg / kg) is injected in a single bolus the mice die within hours. Mice can tolerate more VCD per day if it is metered out over the 24 h time period. Our preliminary data indicates that mice tolerate VCD well when dosed 3 times a day @80 mg / kg / d (total 240 mg / kg / d). Three injections a day, per mouse, is labor intense and may be impractical for commercial production.

[0084]VCD is a member of the 4-vinylcyclohexene family of chemicals and appears to be the bioactive compound in rats and mice. It is...

example 3

Using the NOAEL from Example 2 to Define the Kinetics of Follicle Depletion and Increase in Plasma FSH, and Determining if Less VCD is Required When Administered by Continuous Delivery

[0093]Completion of the Example 2 will provide evidence that continuous delivery of VCD by minipump will not cause general toxicity and accomplish follicle depletion similar to 15 daily VCD injections. The VCD NOAEL will be used to analyze the detailed time course of follicle depletion and increased plasma FSH.

[0094]The VCD NOAEL will be used in Alzet minipump model 1002 that delivers the reservoir volume in 14 days. There will be 4 groups of d40 female mice, 6 mice / group, killed at each time point. Groups 1 and 2 will receive 15 daily injections of 50% DMSO vehicle and 50% DMSO with VCD (160 mg / kg, i.p.). Groups 3 and 4 will receive minipumps implanted sc. loaded with 50% DMSO vehicle and 50% DMSO with VCD. Mice will be monitored for 24 h after the implantation to watch for normal feeding and behavior...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to an animal model for human perimenopause and menopause. Also provided by the present invention are methods of making the animal model and methods of screening using the model. Also provided are methods of inducing ovarian failure in animals such as pets and wildlife.

Description

CONTINUING APPLICATION DATA[0001]This application claims the benefit of the filing date of U.S. provisional application Ser. No. 60 / 406,671, filed on Aug. 29, 2002, the contents of which are incorporated herein by reference.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH[0002]This invention was supported by NIH via grant numbers RO1-ES9246, RO1-ES8979, and RO1-AG021948. The government may have certain rights to this technology.BACKGROUND OF THE INVENTION[0003]1. Field of the Invention[0004]The present invention relates to an animal model for human perimenopause and menopause. Also provided by the present invention are methods of making the animal model and methods of screening and using the model. Also provided are methods of inducing ovarian failure in animals such as pets and wildlife.[0005]2. Description of the Background[0006]The average age of menopause in women in the U.S. is 51 years. Demographic studies on the age of menopause have shown that it has increased from about 45 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K31/336A01K67/00G01N33/00A61K31/015A61P15/18A01KC12N15/00G01N33/50
CPCG01N33/5088A61P15/18
InventorHOYER, PATRICIA B.MAYER, LORETTA P.
OwnerTHE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA